Abstract: The present invention provides processes for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives, which are useful as a Janus kinase (JAK) inhibitor, intermediates thereof, and processes for preparing the intermediates. The present invention provides processes for preparing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile using salts of (3S,4R)-1-benzyl-3-methyl-1,6-diazaspiro[3.4]octane with organic acids.

Abstract: The present invention provides processes for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives, which are useful as a Janus kinase (JAK) inhibitor, intermediates thereof, and processes for preparing the intermediates. The present invention provides processes for preparing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile using salts of (3S,4R)-1-benzyl-3-methyl-1,6-diazaspiro[3.4]octane with organic acids.

Abstract: The present invention provides processes for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives, which are useful as a Janus kinase (JAK) inhibitor, intermediates thereof, and processes for preparing the intermediates. The present invention provides processes for preparing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile using salts of (3S,4R)-1-benzyl-3-methyl-1,6-diazaspiro[3.4]octane with organic acids.

Abstract: The present invention provides processes for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives, which are useful as a Janus kinase (JAK) inhibitor, intermediates thereof, and processes for preparing the intermediates. The present invention provides processes for preparing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile using salts of (3S,4R)-1-benzyl-3-methyl-1,6-diazaspiro[3.4]octane with organic acids.

Abstract: A production method of a compound represented by the formula [I]: or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

Abstract: The present invention provides processes for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives, which are useful as a Janus kinase (JAK) inhibitor, intermediates thereof, and processes for preparing the intermediates. The present invention provides processes for preparing 3-[(3S, 4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile using salts of (3S,4R)-1-benzyl-3-methyl-1,6-diazaspiro[3.4]octane with organic acids.

Abstract: A production method of a compound represented by the formula [I]: or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

Abstract: The present invention provides an Al—Mg series alloy sheet of high-Mg with improved press formability and homogeneity which can be applied to automobile outer panels and inner panels. This is an Al—Mg series aluminum alloy sheet having 0.5 to 3 mm in thickness cast by twin-roll continuous casting and cold rolled, comprising over 8% but not more than 14% Mg, 1.0% or less Fe, and 0.5% or less Si with the remainder being Al and unavoidable impurities wherein the mean conductivity of the aluminum alloy sheet is in the range of at least 20 IACS % but less than 26 IACS %, the strength-ductility balance (tensile strength×total elongation) as a material property of the aluminum alloy sheet is 11000 (MPa %) or more, and the homogeneity and press formability of the sheet have been improved.

Abstract: Skin material of a clad material is composed of one or more layers, each layer of the skin materials is made of a metal different from the core material in their component compositions, and at least one layer of the skin material has a cast microstructure, when the skin material is superposed on either of one or both faces of the core material.

Abstract: Equipment for manufacturing skin material of a clad material includes a casting apparatus which melts and mixes a metal for the skin material different from the core material in their component compositions, and casts the skin material; an ingot-cutting apparatus which cuts an ingot for skin material which is cast by the casting apparatus; and a conveying apparatus which conveys the ingot for skin material among each apparatus. The ingot-cutting apparatus is a slicing apparatus which slices the ingot for skin material into a predetermined thickness.

Abstract: A method for manufacturing a clad material composed of a core material and one or more skin materials which are superposed on either one or both faces of the core material, includes a clad material preparation process where an ingot for core material is manufactured by dissolving and casting a metal, and an ingot for skin material is manufactured by dissolving and casting a different metal for skin material, without hot rolling. The ingot for skin material is superposed as a skin material at a predetermined position of either one or both faces of the ingot for core material and the superposed material is hot-rolled to manufacture a clad material.

Abstract: A method for manufacturing a clad material composed of a core material and one or more skin materials which are superposed on either one or both faces of the core material, includes a clad material preparation process where an ingot for core material is manufactured by dissolving and casting a metal, and an ingot for skin material is manufactured by dissolving and casting a different metal for skin material, without hot rolling. The ingot for skin material is superposed as a skin material at a predetermined position of either one or both faces of the ingot for core material and the superposed material is hot-rolled to manufacture a clad material.

Abstract: A method for manufacturing a clad material composed of a core material and one or more skin materials which are superposed on either one or both faces of the core material, includes a clad material preparation process where an ingot for core material is manufactured by melting and casting a metal, and an ingot for skin material is manufactured by melting and casting a different metal for skin material, without hot rolling. The ingot for skin material is superposed as a skin material at a predetermined position of either one or both faces of the ingot for core material and the superposed material is hot-rolled to manufacture a clad material.

Abstract: Equipment for manufacturing skin material of a clad material includes a casting apparatus which melts and mixes a metal for the skin material different from the core material in their component compositions, and casts the skin material; an ingot-cutting apparatus which cuts an ingot for skin material which is cast by the casting apparatus; and a conveying apparatus which conveys the ingot for skin material among each apparatus. The ingot-cutting apparatus is a slicing apparatus which slices the ingot for skin material into a predetermined thickness.

Abstract: Skin material of a clad material is composed of one or more layers, each layer of the skin materials is made of a metal different from the core material in their component compositions, and at least one layer of the skin material has a cast microstructure, when the skin material is superposed on either of one or both faces of the core material.

Abstract: The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein R1 is —(CH2)m—X—(CH2)n-A1 etc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and A1 is a substituted C3-14 hydrocarbon ring group, etc.; R2 and R3 are the same or different and each is a hydrogen atom, —(CH2)p—X1—(CH2)q-A2, etc., wherein p and q are the same or different and each is 0 to 6, X1 is a single bond, etc. and A2 is an optionally substituted C3-14 hydrocarbon ring group, etc.; R4 is —CO2R9, etc., wherein R9 is a hydrogen atom, etc.; and R20 and R21 are the same or different and each is a hydrogen atom, —(CH2)m12—X12—(CH2)m12—R30, etc., wherein m12 and m12 are the same or different and each is 0 to 6, X12 is a single bond, etc. and R30 is a hydrogen atom, etc.

Abstract: An aluminum alloy sheet contains 0.1% to 0.4% by mass of Cu, 0.5% to 1.5% by mass of Mg, 0.5% to 1.5% by mass of Mn, 0.2% to 0.7% by mass of Fe, and 0.1% to 0.3% by mass of Si. The number density of Al—Mn—Fe—Si-based intermetallic compound having a maximum length of 8 to 15 ?m per unit area is 179 grains/mm2 or less. An oxide film having an average thickness of 30 nm or less is formed on the surface of the aluminum alloy sheet. The arithmetic average roughness Ra of the surface of the aluminum alloy sheet is 0.30 to 0.45 ?m.

Abstract: The present invention provides a method for manufacturing a clad material and the equipment for manufacturing the clad material, in which the productivity is excellent, the surface state and the flatness of the clad material can be readily controlled and the deterioration in adhesion rarely occurs in the clad material.

Abstract: The present invention provides an Al—Mg series alloy sheet of high-Mg with improved press formability and homogeneity which can be applied to automobile outer panels and inner panels. This is an Al—Mg series aluminum alloy sheet having 3.5 to 3 mm in thickness cast by twin-roll continuous casting and cold rolled, comprising over 8% but not more than 14% Mg, 1.0% or less Fe, and 3.5% or less Si with the remainder being Al and unavoidable impurities wherein the mean conductivity of the aluminum alloy sheet is in the range of at least 20 IACS % but less than 26 IACS %, the strength-ductility balance (tensile strength×total elongation) as a material property of the aluminum alloy sheet is 11000 (MPa %) or more, and the homogeneity and press formability of the sheet have been improved.

Abstract: The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein R1 is —(CH2)m—X—(CH2)n-A1 etc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and A1 is a substituted C3-14 hydrocarbon ring group, etc.; R2 and R3 are the same or different and each is a hydrogen atom, —(CH2)p—X1—(CH2)q-A2, etc., wherein p and q are the same or different and each is 0 to 6, X1 is a single bond, etc. and A2 is an optionally substituted C3-14 hydrocarbon ring group, etc.; R4 is —CO2R9, etc., wherein R9 is a hydrogen atom, etc.; and R20 and R21 are the same or different and each is a hydrogen atom, —(CH2)m12—X12—(CH2)m12—R30 etc., wherein m12 and m12 are the same or different and each is 0 to 6, X12 is a single bond, etc. and R30 is a hydrogen atom, etc.